1. Home
  2. LOCL vs RFL Comparison

LOCL vs RFL Comparison

Compare LOCL & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Local Bounti Corporation

LOCL

Local Bounti Corporation

N/A

Current Price

$1.15

Market Cap

25.6M

ML Signal

N/A

Logo Rafael Holdings Inc. Class B

RFL

Rafael Holdings Inc. Class B

N/A

Current Price

$1.48

Market Cap

61.1M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
LOCL
RFL
Founded
2021
2017
Country
United States
United States
Employees
333
N/A
Industry
Farming/Seeds/Milling
Real Estate
Sector
Consumer Staples
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
25.6M
61.1M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
LOCL
RFL
Price
$1.15
$1.48
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
23.4K
91.0K
Earning Date
01-01-0001
03-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
28.28
EPS
N/A
N/A
Revenue
N/A
$917,000.00
Revenue This Year
$36.93
N/A
Revenue Next Year
$82.62
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
43.96
52 Week Low
$0.98
$1.12
52 Week High
$5.75
$3.19

Technical Indicators

Market Signals
Indicator
LOCL
RFL
Relative Strength Index (RSI) 28.07 65.63
Support Level N/A $1.41
Resistance Level $2.75 $1.63
Average True Range (ATR) 0.14 0.10
MACD -0.02 0.02
Stochastic Oscillator 16.06 71.25

Price Performance

Historical Comparison
LOCL
RFL

About LOCL Local Bounti Corporation

Local Bounti Corp is a controlled environment agriculture company. Its business model is based on building local facilities, operated by local teams, to deliver fresh and quality produce to local communities while maintaining a limited carbon footprint. Using proprietary technology to grow leafy greens and herbs in smart greenhouses with a cultivation process that uses less water and land than conventional agriculture, free from herbicides or pesticides, it delivers products that have a longer shelf life, and are good in taste.

About RFL Rafael Holdings Inc. Class B

Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.

Share on Social Networks: